Zacks Investment Research lowered shares of TRACON Pharmaceuticals (NASDAQ:TCON) from a buy rating to a hold rating in a report published on Friday, January 5th. They currently have $4.00 target price on the biopharmaceutical company’s stock.
According to Zacks, “TRACON Pharmaceuticals, Inc. is a biopharmaceutical company. The company’s product candidate includes TRC105, TRC205 and TRC102 which are in different clinical stage for cancer, age-related macular degeneration and fibrotic diseases. TRACON Pharmaceuticals, Inc. is headquartered in San Diego, California. “
Shares of TRACON Pharmaceuticals (NASDAQ TCON) traded down $0.30 during midday trading on Friday, hitting $2.90. 245,200 shares of the company’s stock were exchanged, compared to its average volume of 218,978. The company has a debt-to-equity ratio of 0.24, a quick ratio of 3.80 and a current ratio of 3.80. The company has a market capitalization of $50.80 and a P/E ratio of -2.38. TRACON Pharmaceuticals has a one year low of $2.00 and a one year high of $5.70.
An institutional investor recently bought a new position in TRACON Pharmaceuticals stock. Candriam Luxembourg S.C.A. bought a new position in shares of TRACON Pharmaceuticals Inc (NASDAQ:TCON) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 143,000 shares of the biopharmaceutical company’s stock, valued at approximately $450,000. Candriam Luxembourg S.C.A. owned about 0.86% of TRACON Pharmaceuticals at the end of the most recent quarter. 34.06% of the stock is currently owned by institutional investors.
About TRACON Pharmaceuticals
TRACON Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.